SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantirs Q3 earnings beat expectations and came with raised full-year and Q4 guidance, with strong U.S. commercial AI growth drawing attention. Bulls celebrated the results, while skeptics argued that a premium valuation and weakness across AI stocks could still pressure shares, contributing to a volatile reaction.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal Q4 earnings report, its first under new CEO John Ternus, is driving attention, with traders focused on holiday-quarter guidance, iPhone demand and rising memory costs effect on margins. Some hope a strong report could steady a battered tech market, while others see high expectations and valuation as leaving room for a selloff.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A tech- and AI-linked selloff is driving concern about the broader market, with traders debating whether worries over AI spending and valuations signal a deeper correction or a buying opportunity. Midterm-election uncertainty and upcoming Apple and Palantir results are adding to volatility, while bulls look for a rebound and bears expect further downside.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs upcoming earnings and guidance dominate discussion as the stock has sold off sharply with semiconductor shares after Intels weak report. Traders are split on whether strong results could spark a rebound or whether valuation concerns and a cautious outlook would extend the decline.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp Nasdaq and technology selloff, with traders focused on whether heavy AI spending can generate adequate returns or whether the AI trade is unwinding. Bearish calls and concern about further losses compete with dip-buying and expectations of a technical bounce; midterm uncertainty is adding to volatility.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvells all-stock agreement to acquire Lumentum has sparked a sharp selloff, with traders focused on shareholder dilution, the long wait for closing, and whether the deals price and execution risks are justified. Some see the combination as a strategic bet on optical connectivity for AI data centers, while others argue the deal undermines value for existing shareholders amid a broader tech selloff.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 trial reached its prespecified 80th death event, triggering final analysis and anticipation of GPS topline results; the milestone was followed by a sharp selloff. Traders disagree over whether the decline reflects profit-taking and binary-trial risk or suspected manipulation or an information leak, with no results yet establishing the trials outcome.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp semiconductor and tech selloff, with traders debating whether concerns about AI spending and a broader risk-off move point to a deeper correction; claims of forced liquidations remain speculation. Dip buyers are looking for a rebound, while bears warn that the funds 3x leverage can magnify losses and decay.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Marvells agreed all-stock acquisition of Lumentum has triggered a sharp selloff, as Lumentum holders focus on the fixed share exchange, exposure to Marvells falling stock and the long path to closing. Traders debate whether the deals dilution and timing make it unfavorable for shareholders or whether the strategic fit in AI optical connectivity supports the combination over the longer term.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A sharp semiconductor-sector pullback, amid worries that heavy AI infrastructure spending may not deliver returns quickly enough and weak guidance from major chipmakers, is driving attention to SOXX. Traders are split between calling the decline an AI-bubble unwind with more downside ahead and treating it as an oversold correction and buying opportunity, with many watching key technical support levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gossamer Bio Submits New Drug Application to U.S. FDA for Seralutinib for the Treatment of Pulmonary Arterial Hypertension

Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease...

Gossamer Bio Appoints Greg Ciongoli to Board of Directors

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced...

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Gossamer Bio, Inc. (Nasdaq: GOSS) (the Company or Gossamer), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today...

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer’s Billion-Dollar Drug Bet Funded with $150M War Chest to Target FDA Approval

Gossamer Bio (NASDAQ:GOSS) is putting serious money behind a high-stakes regulatory bet. The company announced a structured private placement that could deliver up to $250 million, including $150 million of committed capital, as Gossamer races toward a planned September 2026 FDA submission for seralutinib in pulmonary arterial hypertension (PAH). The structure is milestone-driven: roughly $25 million is expected at the initial closing, another $125 million becomes available if the FDA accepts the NDA in 2026, and warrants could provide up to another $100 million if seralutinib ultimately receives FDA approval.

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) delivered earnings and revenue surprises of -100.00% and +171.71%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Pelthos Therapeutics Inc. (PTHS) Reports Q2 Loss, Lags Revenue Estimates

Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of -119.21% and -2.88%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.

Gossamer Bio Inc

Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash?

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Participants treated with seralutinib recorded a median improvement of 28.2 meters in walking distance, compared with 13.5 meters with placebo.</li><li>The estimated treatment benefit was 13.3 meters, with a p-value of 0.032, falling short of the predefined significance cutoff of 0.025.</li><li>In a predefined subgroup of intermediate- and high-risk individuals, seralutinib delivered a more pronounced benefit.</li></ul>Gossamer Bio Inc. (GOSS) on Monday released topline findings from its late-stage PROSERA trial evaluating seralutinib in patients with pulmonary arterial hypertension (PAH), offering a mixed picture as the company weighs its regulatory strategy.The Phase 3 study assessed the experimental therapy over 24 weeks, measuring improvement in six-minute walk distance compared with placebo.&nbsp;<h2 class="st-heading-2">Primary Endpoint Falls Short</h2>The drug did not achieve the predefined statistical bar for its main goal. Participants treated with seralutinib recorded a median improvement of 28.2 meters in walking distance, compared with 13.5 meters among placebo recipients.&nbsp;The estimated treatment benefit was 13.3 meters, with a p-value of 0.032, falling short of the predefined significance cutoff of 0.025. As a result, the secondary endpoints cannot be formally considered statistically significant, though all four key secondary measures favored seralutinib.Following the announcement,&nbsp;<a href="https://stocktwits.com/symbol/GOSS">Gossamer Bio's stock</a> traded over 82% lower on Monday mid-morning. On Stocktwits, retail sentiment around the stock remained in ‘extremely bullish’ territory while message volume shifted to ‘extremely high’ from high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_02_23_105719_png_f367574236.webp" alt="GOSS’s Sentiment Meter and Message Volume as of 10:40 a.m. ET on Feb. 23, 2026 | Source: Stocktwits" width="931" height="100"><figcaption>GOSS’s Sentiment Meter and Message Volume as of 10:40 a.m. ET on Feb. 23, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Stronger Results In Higher-Risk Patients</h2>In a predefined subgroup of intermediate- and high-risk individuals, seralutinib delivered a more pronounced benefit. That cohort achieved a 20-meter placebo-adjusted increase in walking distance, along with favorable results across most secondary markers.Patients with connective tissue disease–associated PAH also demonstrated a notable response, with a placebo-adjusted increase of 37 meters in walking distance at 24 weeks.&nbsp;The company plans to meet with the U.S. Food and Drug Administration to determine a regulatory path forward. Gossamer has paused enrollment in SERANATA study to assess the implications of PROSERA’s outcome.GOSS stock has declined by over 70% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-allurion-stock-surge-today/cZRtuSER4yS">Why Did Allurion Stock Surge Over 50% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A view from lab as Ankara University Faculty of Pharmacy, Department of Basic Pharmaceutical Sciences.

Gossamer Bio’s seralutinib did not achieve the predefined statistical bar for its main goal in the phase 3 PROSERA trial. 

Up more than 3%

Flat to up 3%

Flat to down 3%

Down more than 3%

What’s your expected total return for the S&amp;P 500 ($SPY) in November?

Stocktwits

What’s your expected total return for the S&P 500 (

Current Price	$9.45
Prev Close	$10.38
Open	$10.30
Dividend Yield	0.00%
50-Day Moving Average	$11.26
Beta	2.14
Avg. Volume	277,664.52
PE Ratio	-0.19

52-Week High	$309.60
52-Week Low	$8.29
Market Capitalization	$63.43M
EPS (Annual)	-$59.64
Price to Book	-0.67
Revenue Per Employee	$299,203.70

Feed

News

Sentiment

Earnings

Fundamentals

Info

GOSS Fundamentals